Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam

European Journal of Clinical Pharmacology

Volumn 51, Issue 5, 1997, Pages 415-419

  Ahonen, J ^a   Olkkola, K T ^a   Neuvonen, P J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CYP3A4; Fluconazole; Interaction; Midazolam; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; DRUG METABOLITE; FLUCONAZOLE; MIDAZOLAM; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM;

EID: 0031028102     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050223     Document Type: Article

References (24)

1. Allonen H, Ziegler G, Klotz U (1981) Midazolam kinetics. Clin Pharmacol Ther 30: 653-661
2. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73: 658-661
3. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643-1653
4. Gascon M-P, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573-578
5. Hargreaves JA, Jezequel S, Houston JB (1994) Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38: 175
6. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53: 298-305
7. Backman J, Olkkola KT, Aranko K, Himberg J-J, Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37: 221-225
8. Olkkola KT, Backman J, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 55: 481-485
9. Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82: 511-516
10. Varhe A, Olkkola KT, Neuvonen PJ (1996) Effect of fluconazole dose on the extent of fluconazole triazolam interaction. Br J Clin Pharmacol, 42: 465-470
11. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144-160
12. Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the aut. Lancet 338: 1488-1490
13. Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ (1993) Determination of midazolam and its 1-hydroxymetabolites in human plasma and urine by high-performance liquid Chromatography. Ther Drug Monit 15: 338-343
14. Inagaki K, Tagaki J, Lor E, Okamoto MP, Gill MA (1992) Determination of fluconazole in human serum by solid-phase extraction and reversed-phase HPLC. Ther Drug Monit 14: 306-311
15. Harris SC, Wallace JE, Foulds G, Rinaldi MG (1989) Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chem 33: 714-716
16. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947-955
17. Guengerich FP (1992) Characterization of human cytochrome P450 enzymes. FASEB J 6: 745-748
18. Kaminsky LS, Fasco MJ (1992) Small intestinal cytochromes P450. Crit Rev Toxicol 21: 407-422
19. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 80: 1029-1036
20. Peter WHM, Kremers PG (1989) Cytochromes P450 in the intestinal mucosa of man. Biochem Pharmacol 38: 1535-1538
21. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58: 492-497
22. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang JD, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878
23. Mandema JW, Tuk B, van Stevenick AL, Breimer DD, Cohen AF, Danhof M (1992) Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51: 715-728
24. Park GR, Manara AR, Dawling S (1989) Extra-hepatic metabolism of midazolam. Br J Clin Pharmacol 27: 634-637